glp-1 kidney protection Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic disease: an approach for the nephrologist glp 1 kidney protection GLP-1

BPC-157 is not approved by the FDA, EMA, or any other regulatory authority for human or veterinary therapeutic use

They bypass the blood-brain barrier

At the beginning of the treatment, 1 ml of vitamin B12 Wiedemann 1 mg/ml (corresponding to 1000 g cyanocobalamin) is administered twice a week in the first weeks after diagnosis Safety Warning Wiedemann Vitamin B12 1 mg/ml contains sodiumbut less than 1 mmol (23 mg) sodium per 1 mli.e

There are studies showing that patients who experience more robust weight loss after MBS have higher levels of GLP-1 as compared with patients who have less favorable weight loss [12, 13, 24,25,26,27,28]